Literature DB >> 18981459

Bevacizumab reverses cerebral radiation necrosis.

Eric T Wong1, Mark Huberman, Xing-Qi Lu, Anand Mahadevan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18981459     DOI： 10.1200/JCO.2008.19.1866

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  38 in total

1.  Favorable outcome with bevacizumab after poor outcome with steroids in a patient with temporal lobe and brainstem radiation necrosis.

Authors:  Amandine Benoit; François Ducray; Stéphanie Cartalat-Carel; Dimitri Psimaras; Damien Ricard; Jérôme Honnorat
Journal:  J Neurol       Date:  2010-09-23       Impact factor: 4.849

Review 2.  Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy.

Authors:  Erqi L Pollom; Lei Deng; Reetesh K Pai; J Martin Brown; Amato Giaccia; Billy W Loo; David B Shultz; Quynh Thu Le; Albert C Koong; Daniel T Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-07-01       Impact factor: 7.038

3.  An analysis of radiation necrosis of the central nervous system treated with bevacizumab.

Authors:  Karen Tye; Herbert H Engelhard; Konstantin V Slavin; M Kelly Nicholas; Steven J Chmura; Young Kwok; Dominic S Ho; Ralph R Weichselbaum; Matthew Koshy
Journal:  J Neurooncol       Date:  2014-02-07       Impact factor: 4.130

Review 4.  Delayed brain radiation necrosis: pathological review and new molecular targets for treatment.

Authors:  Motomasa Furuse; Naosuke Nonoguchi; Shinji Kawabata; Shin-Ichi Miyatake; Toshihiko Kuroiwa
Journal:  Med Mol Morphol       Date:  2015-12       Impact factor: 2.309

5.  Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials.

Authors:  Julie A Carlson; Krishna Reddy; Laurie E Gaspar; Douglas Ney; Brian D Kavanagh; Denise Damek; Kevin Lillehei; Changhu Chen
Journal:  J Neurooncol       Date:  2015-04-29       Impact factor: 4.130

6.  Presence of Histopathological Treatment Effects at Resection of Recurrent Glioblastoma: Incidence and Effect on Outcome.

Authors:  Cecilia L Dalle Ore; Ankush Chandra; Jonathan Rick; Darryl Lau; Maryam Shahin; Alan T Nguyen; Michael McDermott; Mitchel S Berger; Manish K Aghi
Journal:  Neurosurgery       Date:  2019-12-01       Impact factor: 4.654

Review 7.  Post-treatment imaging changes in primary brain tumors.

Authors:  Barbara J O'Brien; Rivka R Colen
Journal:  Curr Oncol Rep       Date:  2014       Impact factor: 5.075

Review 8.  The role of brachytherapy in the treatment of glioblastoma multiforme.

Authors:  Eric Barbarite; Justin T Sick; Emmanuel Berchmans; Amade Bregy; Ashish H Shah; Nagy Elsayyad; Ricardo J Komotar
Journal:  Neurosurg Rev       Date:  2016-05-16       Impact factor: 3.042

9.  Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas.

Authors:  Arthur K Liu; Margaret E Macy; Nicholas K Foreman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-11-15       Impact factor: 7.038

10.  A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema.

Authors:  Yang Wang; Enmin Wang; Li Pan; Jiazhong Dai; Nan Zhang; Xin Wang; Xiaoxia Liu; Guanghai Mei; Xiaofang Sheng
Journal:  J Neurooncol       Date:  2014-05-31       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.